AI protein design startup Tushen Zhihe raises hundreds of millions RMB across two rounds

机器之心 · wechat · 2026-11-17

Wuxi-based Tushen Zhihe, an AI protein design startup founded in 2023, closed back-to-back Pre-A and Pre-A+ rounds totaling hundreds of millions of RMB. Pre-A was led by Shanghai S&T Venture Capital; Pre-A+ was co-invested by Jinding Capital, Mgger Technology, Qingke Holdings and others.

Its ToursynClaw platform runs a full wet-lab-dry-lab loop of "design–experiment–feedback–redesign": AI-generated protein candidates are validated by automated high-throughput wet labs, with data flowing back to iteratively refine design strategies. The company has validated over 100 antibody engineering projects, generated 5,000+ experimental data points, and completes a design-validation cycle in 14 days, targeting hard-to-drug targets like GPCRs and intrinsically disordered regions.

Funds will advance internal pipelines toward IND filings, upgrade the platform's protein generation models, and expand partnerships and out-licensing with domestic and multinational pharma companies.

Original post →

More from Venture

Venture channel →